News
14h
Investment Monitor on MSNRisk of tariff-triggered global recession growing – GlobalDataConcerns over a potential US recession this year are growing as investors assess the impact of Trump's tariff policies.
Companies are reporting first-quarter earnings now, but the next round of results are expected to reveal the effects of tariff-driven volatility that began in March. Investors will be looking for ...
"LUBBC strengthens manufacturing capacity through expanded alliance with SIG" was originally created and published by Packaging Gateway, a GlobalData owned brand. The information on this site has been ...
7d
Pharmaceutical Technology on MSNPharma industry dodges tariff blow but still braces for disruptionAccording to a factsheet published by the Trump administration, pharmaceuticals are exempted from the tariffs – for now.
While many expect all-time highs of cryptocurrency in 2025, analysis of the market suggests that uncertainty will remain.
14d
Medical Device Network on MSNFDA clears Bolt Medical’s IVL system, backing Boston Scientific’s $664m buyoutThe intravascular lithotripsy market has undergone high growth trailblazed by J&J subsidiary Shockwave Medical.
GlobalData has cut its 2025 global light vehicle (LV) production forecast by 300,000 units, which now stands at 92.3 million (+2.4% YoY) for the year. The data intelligence company says a more ...
The insurance sector continues to encounter consumer hesitation around artificial intelligence, even as users report positive ...
11d
Clinical Trials Arena on MSNLundbeck’s superagonist prompts 61.2% seizure reductionResults from Lundbeck's open-label portion of the Pacific trial saw bexicaserin able to elicit seizure reduction in treatment ...
11d
Clinical Trials Arena on MSNAre DCTs truly more sustainable?DCTs were readily adopted during the pandemic, with many believing they were more sustainable, but experts are now ...
GlobalData Plc (LON:DATA – Get Free Report)’s share price reached a new 52-week low on Monday .The company traded as low as GBX 155.71 ($2.02) and last traded at GBX 155.71 ($2.02), with a ...
GlobalData predicts that tirzepatide is likely to be increasingly prescribed for broader cardiometabolic disease.
Results that may be inaccessible to you are currently showing.
Hide inaccessible results